132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc

Posted by Francis Steltz on Aug 31st, 2026

Legal & General Group Plc acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 132,351 shares of the company’s stock, valued at approximately $16,224,000. Legal & General Group Plc owned 0.20% of Protagonist Therapeutics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Royal Bank of Canada raised its position in shares of Protagonist Therapeutics by 30.6% during the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after acquiring an additional 2,334 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Protagonist Therapeutics by 0.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock worth $1,810,000 after purchasing an additional 348 shares during the last quarter. Millennium Management LLC grew its stake in shares of Protagonist Therapeutics by 283.6% during the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock worth $6,493,000 after purchasing an additional 99,269 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Protagonist Therapeutics during the second quarter worth $987,000. Finally, Guggenheim Capital LLC increased its holdings in Protagonist Therapeutics by 1.6% in the second quarter. Guggenheim Capital LLC now owns 19,208 shares of the company’s stock valued at $1,062,000 after purchasing an additional 303 shares during the last quarter. 98.63% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays increased their price target on shares of Protagonist Therapeutics from $151.00 to $153.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Zacks Research lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 7th. Truist Financial upped their price objective on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Johnson Rice set a $165.00 price objective on Protagonist Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen raised Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $140.53.

Read Our Latest Research Report on PTGX

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $144.33 on Monday. Protagonist Therapeutics, Inc. has a 12-month low of $54.50 and a 12-month high of $160.81. The firm’s 50 day moving average is $138.51 and its 200-day moving average is $112.70. The company has a market capitalization of $9.34 billion, a PE ratio of 140.13 and a beta of 1.78.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.27 by $0.02. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm had revenue of $213.47 million for the quarter, compared to analysts’ expectations of $212.03 million. Protagonist Therapeutics’s revenue for the quarter was up 3746.8% compared to the same quarter last year. As a group, sell-side analysts expect that Protagonist Therapeutics, Inc. will post 4.22 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $149.11, for a total transaction of $9,805,622.71. Following the transaction, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $78,055,804.58. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 118,000 shares of company stock worth $16,921,379. 5.19% of the stock is owned by corporate insiders.

Protagonist Therapeutics Company Profile

(Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.